HEALTH PROFESSIONAL · SOURCE READING

Fulvestrant

Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 25, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Metastatic Breast Cancer / Metastatic HER2-Negative Hormone Receptor–Positive Breast Cancer / Endocrine therapy alone

Fulvestrant is a selective estrogen receptor degrader that has been studied in the first-line and second-line setting in women with advanced or metastatic breast cancer.

Continue within this section

First-line fulvestrant →Second-line fulvestrant →

Preserved source evidence · Not medical advice